Geode Capital Management LLC cut its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 13.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,576,658 shares of the life sciences company's stock after selling 247,336 shares during the period. Geode Capital Management LLC owned 2.04% of Integra LifeSciences worth $35,767,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Integra LifeSciences during the 4th quarter valued at $8,967,000. Access Investment Management LLC acquired a new position in Integra LifeSciences during the 4th quarter valued at about $4,416,000. Cannell & Spears LLC purchased a new stake in Integra LifeSciences in the fourth quarter valued at about $3,555,000. JPMorgan Chase & Co. boosted its holdings in Integra LifeSciences by 130.5% in the fourth quarter. JPMorgan Chase & Co. now owns 199,691 shares of the life sciences company's stock worth $4,529,000 after acquiring an additional 113,061 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Integra LifeSciences by 10.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,047,573 shares of the life sciences company's stock worth $23,759,000 after acquiring an additional 103,291 shares during the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.
Integra LifeSciences Stock Performance
IART traded up $0.48 on Tuesday, reaching $15.67. The stock had a trading volume of 732,574 shares, compared to its average volume of 1,042,671. The business's 50-day moving average price is $20.95 and its two-hundred day moving average price is $22.23. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 12-month low of $14.45 and a 12-month high of $32.66. The company has a market cap of $1.21 billion, a P/E ratio of -174.09, a price-to-earnings-growth ratio of 0.73 and a beta of 1.24.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, topping analysts' consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company had revenue of $442.65 million during the quarter, compared to analysts' expectations of $445.15 million. During the same quarter in the prior year, the firm posted $0.89 EPS. Integra LifeSciences's quarterly revenue was up 11.5% compared to the same quarter last year. Sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.
Analyst Upgrades and Downgrades
IART has been the subject of several research analyst reports. Truist Financial reduced their price objective on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Argus raised shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research report on Monday, March 31st. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $22.71.
Get Our Latest Report on Integra LifeSciences
About Integra LifeSciences
(
Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Featured Stories
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
